Products
Mirvetuximab Soravtansine Biosimilar Antibody-Drug Conjugate (Folate Receptor α) for Research
Pre-made Mirvetuximab Soravtansine benchmark antibody (Whole mAb ADC, anti-FOLR1 therapeutic antibody, Anti-FBP/FOLR/FRalpha/NCFTD Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
ImmunoGen, Inc. (Nasdaq: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.[2]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-914-1mg | 1mg | |
| GMP-Bios-INN-914-10mg | 10mg | |
| GMP-Bios-INN-914-100mg | 100mg | |
| GMP-Bios-INN-914-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Mirvetuximab Soravtansine Biosimilar, Whole Mab Adc, Anti-Folr1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody Drug Conjugate |
| INN Name | Mirvetuximab Soravtansine |
| Target | FOLR1 |
| Format | Whole mAb ADC |
| Derivation | Chimeric |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | ImmunoGen Inc. (Cambridge MA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - FOLR1
1. Protein Folate receptor alpha
2. Gene FOLR1
3. Organism Homo sapiens (Human)
Function
Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation.
